Cheminformatic Tools and Databases for Pharmacology

session 93082 - Total of 1 hits - Display   hits per page:

Add another drug(s) by one keyword:
Exemple: “nib“ and click on the Search button (do not press Enter on the keyboard)

1 INNClassRoute (list)PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)Primary Target and PDB code of Protein-Drug complexTargets from DrugCentral Links
LENVATINIB

LENVATINIB


ATC L01XE29

ANTINEOPLASTIC
TREATMENT OF THYROID CANCER
RECEPTOR TYROSINE KINASE (RTK) INHIBITOR
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTORS VEGFR1 (FLT1), VEGFR2 (KDR) AND VEGFR3 (FLT4) INHIBITOR
FIBROBLAST GROWTH FACTOR (FGF) RECEPTORS FGFR1, 2, 3, AND 4 INHIBITOR
PDGFRALPHA, KIT AND RET INHIBITOR

ORAL

Tmax 2.5 HOUR

F 85 PERCENT

VD 82 LITER

PPB 98.5 PERCENT

HT 28 HOUR

SOLUBILITY SLIGHTLY SOLUBLE IN WATER

VEGFR RECEPTORS

PDB 3WZD (KDR IN COMPLEX WITH LIGAND LENVATINIB)

LIGAND CODE = LEV (link to the list of PDB complexes)

Download experimental 3D coordinates of LEV with added hydrogens

PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET P07949 PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET HOMO SAPIENS ENZYME KINASE PROTEIN KINASE TK RETANSM (in French)

Dailymed
Drugs.com

SIDER side effects

Chemical Probes Portal

ChEMBL
BindingDB
DrugBank



Copyright © 2019 Université Côte d'Azur CNRS - All rights reserved
  | Contact |